GPX4 promotes proliferation and ferroptosis resistance in lung cancer, while GPX4 inhibitor RSL3 limits proliferation, migration, and invasion of cisplatin-resistant A549 cells (Deng et al., 2021). The gene discussed is GPX4; the disease is lung carcinoma.